Primordial magnetic field as a common solution of nanohertz gravitational waves and Hubble tension

The origin of interstellar and intergalactic magnetic fields is largely unknown, and the primordial magnetic fields (PMFs) produced by, e.g., phase transitions of the early Universe are expected to provide seeds for those magnetic fields. The PMFs affect the evolution of the Universe at an early time, resulting in a series of phenomena. In this work, we show that the PMF-induced turbulence can give rise to nanohertz (nHz) gravitational waves reported by several pulsar timing arrays, including NANOGrav, PPTA, EPTA, and CPTA. Using the nHz gravitational wave data, we obtain the constraints on the characteristic magnetic field strength ($B_{\rm ch}^* \sim \mathcal{O}(1)~\rm{\mu G}$) and coherent length scale ($\ell_{\rm ch}^* \sim \mathcal{O}(1)~\rm{pc}$) of PMFs, assuming a generation temperature of approximately the QCD temperature ($\sim 100$ MeV). In addition, the PMFs which evolve to the recombination era can induce baryon density inhomogeneities, and then alter the ionization process. This naturally results in an alleviation of the tension of the Hubble parameter $H_0$ and the matter clumpiness parameter $S_8$ between early and late-time measurements. Assuming an evolution form of $B_{\rm ch}\sim \ell_{\rm ch}^{-\alpha}$ from the epoch of the production of PMFs to the epoch of recombination, we find $0.91<\alpha<1.08$ (95\% credible region).Comment: 7 pages, 4 figure

Acute effect of particulate matter pollution on hospital admissions for cause-specific respiratory diseases among patients with and without type 2 diabetes in Beijing, China, from 2014 to 2020

BACKGROUND: Scientific studies have identified various adverse effects of particulate matter (PM) on respiratory disease (RD) and type 2 diabetes (T2D). However, whether short-term exposure to PM triggers the onset of RD with T2D, compared with RD without T2D, has not been elucidated. METHODS: A two-stage time-series study was conducted to evaluate the acute adverse effects of PM on admission for RD and for RD with and without T2D in Beijing, China, from 2014 to 2020. District-specific effects of PM and PM were estimated using the over-dispersed Poisson generalized addictive model after adjusting for weather conditions, day of the week, and long-term and seasonal trends. Meta-analyses were applied to pool the overall effects on overall and cause-specific RD, while the exposure-response (E-R) curves were evaluated using a cubic regression spline. RESULTS: A total of 1550,154 admission records for RD were retrieved during the study period. Meta-analysis suggested that per interquartile range upticks in the concentration of PM corresponded to 1.91% (95% CI: 1.33-2.49%), 2.16% (95% CI: 1.08-3.25%), and 1.92% (95% CI: 1.46-2.39%) increments in admission for RD, RD with T2D, and RD without T2D, respectively, at lag 0-8 days, lag 8 days, and lag 8 days. The effect size of PM was statistically significantly higher in the T2D group than in the group without T2D (z = 3.98, P \u3c 0.01). The effect sizes of PM were 3.86% (95% CI: 2.48-5.27%), 3.73% (95% CI: 1.72-5.79%), and 3.92% (95% CI: 2.65-5.21%), respectively, at lag 0-13 days, lag 13 days, and lag 13 days, respectively, and no statistically significant difference was observed between T2D groups (z = 0.24, P = 0.81). Significant difference was not observed between T2D groups for the associations of PM and different RD and could be found between three groups for effects of PM on RD without T2D. The E-R curves varied by sex, age and T2D condition subgroups for the associations between PM and daily RD admissions. CONCLUSIONS: Short-term PM exposure was associated with increased RD admission with and without T2D, and the effect size of PM was higher in patients with T2D than those without T2D

Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion

The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied. In a multicenter trial in China, we enrolled patients with ischemic stroke without occlusion of large or medium-sized vessels and with a National Institutes of Health Stroke Scale score of 5 or more and at least one moderately to severely weak limb. Eligible patients had any of four clinical presentations: ineligible for thrombolysis or thrombectomy and within 24 hours after the patient was last known to be well; progression of stroke symptoms 24 to 96 hours after onset; early neurologic deterioration after thrombolysis; or thrombolysis with no improvement at 4 to 24 hours. Patients were assigned to receive intravenous tirofiban (plus oral placebo) or oral aspirin (100 mg per day, plus intravenous placebo) for 2 days; all patients then received oral aspirin until day 90. The primary efficacy end point was an excellent outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. Secondary end points included functional independence at 90 days and a quality-of-life score. The primary safety end points were death and symptomatic intracranial hemorrhage. A total of 606 patients were assigned to the tirofiban group and 571 to the aspirin group. Most patients had small infarctions that were presumed to be atherosclerotic. The percentage of patients with a score of 0 or 1 on the modified Rankin scale at 90 days was 29.1% with tirofiban and 22.2% with aspirin (adjusted risk ratio, 1.26; 95% confidence interval, 1.04 to 1.53, P = 0.02). Results for secondary end points were generally not consistent with the results of the primary analysis. Mortality was similar in the two groups. The incidence of symptomatic intracranial hemorrhage was 1.0% in the tirofiban group and 0% in the aspirin group. In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

Importance It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy. Objective To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO. Design, Setting, and Participants This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.InterventionsEligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy. Main Outcomes and Measures The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours. Results Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo. Conclusions and Relevance Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.Trial RegistrationChiCTR.org.cn Identifier: ChiCTR210005172

Ligand-modulated nickel-catalyzed regioselective silylalkylation of alkenes

Abstract Organosilicon compounds have shown tremendous potential in drug discovery and their synthesis stimulates wide interest. Multicomponent cross-coupling of alkenes with silicon reagents is used to yield complex silicon-containing compounds from readily accessible feedstock chemicals but the reaction with simple alkenes remains challenging. Here, we report a regioselective silylalkylation of simple alkenes, which is enabled by using a stable Ni(II) salt and an inexpensive trans−1,2-diaminocyclohexane ligand as a catalyst. Remarkably, this reaction can tolerate a broad range of olefins bearing various functional groups, including alcohol, ester, amides and ethers, thus it allows for the efficient and selective assembly of a diverse range of bifunctional organosilicon building blocks from terminal alkenes, alkyl halides and the Suginome reagent. Moreover, an expedient synthetic route toward alpha-Lipoic acid has been developed by this methodology

Energy-aware intelligent scheduling for deadline-constrained workflows in sustainable cloud computing

It is challenging to handle the non-linear power consumption model, complex workflow structures, and diverse user-defined deadlines for energy-efficient workflow scheduling in sustainable cloud computing. Although metaheuristics are very attractive to solve this problem, most of the existing work regards the problem as a black-box and ignores the use of domain knowledge. To make up for their shortcomings, this paper tailors an energy-aware intelligent scheduling algorithm (EIS) with three new mechanisms. First, we derive the optimal execution time that minimizes energy consumption for each task on a given resource. Second, based on the optimal execution time of each workflow task, the EIS distributes the workflow slack time (difference between its completion time and deadline) to reduce the voltages and frequencies of task executions for energy saving. Third, the EIS mines the idle time gaps caused by task precedence constraints to further reduce dynamic energy consumption whilst satisfying workflows’ deadline constraints. To measure the performance of the EIS, we conduct extensive comparison experiments based on actual workflow applications. The results demonstrate that the energy consumption of the EIS is much lower than that of the competitors under different deadlines, and has a faster descend rate with the evolution process

Photocatalytic Oxidative Coupling of Methane to Ethane Using Water and Oxygen on Ag₃PO₄‑ZnO

Photocatalytic oxidative coupling is an effective way of converting CH4 to high-value-added multi-carbon chemicals under mild conditions, where the breaking of the C–H bond is the main rate-limiting step. In this paper, the Ag3PO4-ZnO heterostructure photocatalyst was synthesized for photocatalytic oxidative coupling of methane (OCM) to C2H6. In addition, an excellent C2H6 yield (16.62 mmol g–1 h–1) and a remarkable apparent quantum yield (15.8% at 350 nm) at 49:1 CH4/Air and 20% RH are obtained, which is more than three times that of the state-of-the-art photocatalytic systems. Ag3PO4 improves the adsorption and dissociation ability of O2 and H2O, benefiting the formation of surface hydroxyl species. As a result, the C–H bond activation energy of CH4 on ZnO was obviously reduced. Meanwhile, the improved separation of photogenerated carriers on the Ag3PO4-ZnO heterostructure also accelerates the OCM process. Moreover, Ag nanoparticles (NPs) derived from Ag3PO4 reduction by photoelectrons promote the coupling of *CH3, which can inhibit the overoxidation of CH4 and increase C2H6 selectivity. This research provides a guide for the design of catalyst and reaction systems in the photocatalytic OCM process

Improved photocatalytic activity of BaTiO3/La2Ti2O7 heterojunction composites via piezoelectric-enhanced charge transfer

The separation efficiency of photogenerated carriers in photocatalysis is one of the key factors limiting the overall performance. The polarization field modification of piezoelectric materials is considered to be an effective strategy to regulate their photocatalytic performance. In this study, novel heterojunction photocatalysts that combine piezoelectric BaTiO3 nanorods and La2Ti2O7 nanosheets were synthesized and the polarization electric field promoted the bulk charge separation, while regulating the migration and separation of the carriers at the heterojunction interface. Under the combined action of visible light and ultrasonic, the piezo-photocatalytic degradation efficiency of CIP over BaTiO3/La2Ti2O7 composites increased by 24% and 12.5% compared with its photocatalytic and piezocatalytic degradation efficiency, respectively. Furthermore, the finite element simulation shows that BaTiO3/La2Ti2O7 heterojunctions have a stronger piezoelectric potential difference compared to pure BaTiO3. Our findings provide insights into the development of piezo-photocatalysts that can effectively degrade pollutants under visible light

Integrated Memristor Network for Physiological Signal Processing

Abstract Humans are complex organisms made by millions of physiological systems. Therefore, physiological activities can represent physical or mental states of the human body. Physiological signal processing is essential in monitoring human physiological features. For example, non‐invasive electroencephalography (EEG) signals can be used to reconstruct brain consciousness and detect eye movements for identity verification. However, physiological signal processing requires high resolution, high sensitivity, fast responses, and low power consumption, hindering practical hardware design for physiological signal processing. The bionic capability of memristor devices is very promising in the context of building physiological signal processing hardware and they have demonstrated a handful of advantages over the traditional Von Neumann architecture system in accelerating neural networks. Memristor networks can be integrated as a hardware system for physiological signal processing that can deliver higher energy efficiency and lower latency compared to traditional implementations. This review paper first introduces memristor characteristics, followed by a comprehensive literature study of memristor‐based networks. Physiology signal processing applications enabled by these integrated memristor networks are also presented in this review. In summary, this paper aims to provide a new perspective on physiological signal processing using integrated memristor networks